Looking Beyond BioNTech/Biotheus To Future Potential China Deals
Bispecifics/ADCs To Attract More Foreign Interest?
BioNTech and Biotheus’s recent acquisition deal and the current tough funding environment for Chinese biotechs may point to further potential transactions at attractive valuations. Bispecific antibodies and ADCs in oncology are possible targets for cross-border deals.
